5-(3-氯苯基)-2-氨基吡啶 | 893738-14-2

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 5-(3-氯苯基)-2-氨基吡啶
• 中文别名: 5-(3-氯苯基)-2-吡啶胺
• 英文名称: 5-(3-chlorophenyl)pyridin-2-amine
• 英文别名: 5-(3-chlorophenyl)pyridin-2-ylamine
• CAS: 893738-14-2
• 化学式: C₁₁H₉ClN₂
• 分子量: 204.659
• InChiKey: YLBIMHAAQBBISK-UHFFFAOYSA-N

物化性质

• 沸点：
  355.4±27.0 °C(Predicted)
• 密度：
  1.261

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  5-(3-氯苯基)-2-氨基吡啶 、 苯甲酰氯 在 吡啶 作用下， 反应 2.0h， 以43%的产率得到N-[5-(3-chlorophenyl)pyridin-2-yl]benzamide
  参考文献：
  名称：

  False Positives in a Reporter Gene Assay: Identification and Synthesis of Substituted N-Pyridin-2-ylbenzamides as Competitive Inhibitors of Firefly Luciferase

  摘要：

  Luciferase reporter-gene assays are a commonly used technique in high-throughput screening campaigns. In this study, we report on a luciferase inhibitor (1), which emerged from an antagonistic G protein-coupled receptor luciferase reporter-gene assay screen. Instead of displaying receptor activity, compound I was shown to potently inhibit luciferase in an in vitro enzymatic assay with an IC50 value of 1.7 +/- 0.1 mu M. In addition, 1 was a competitive inhibitor with respect to the substrate luciferin. A database search yielded another inhibitor (3) with a similar N-pyridin-2-ylbenzamide core. Subsequently, several analogues were prepared to investigate the structure-activity relationships of these luciferase inhibitors. This yielded the most potent inhibitor of this series (6) with an IC50 value of 0.069 +/- 0.01 mu M. Further molecular modeling studies suggested that 6 can be accommodated in the luciferin binding site. This paper is meant to alert users of luciferase reporter-gene assays for possible false positive hits including highly "druglike" molecules due to direct luciferase inhibition.

  DOI：

  10.1021/jm8004509
• 作为产物：
  描述：

  2-氨基-5-溴吡啶 、 3-氯苯硼酸 在 bis-triphenylphosphine-palladium(II) chloride 、 sodium carbonate 作用下， 以 甲醇 、 甲苯 为溶剂， 生成 5-(3-氯苯基)-2-氨基吡啶
  参考文献：
  名称：

  新型吡啶连接咪唑并[1,2-a]吡啶衍生物的设计、合成、体外α-葡萄糖苷酶抑制、抗氧化活性和分子对接研究

  摘要：

  设计并通过Suzuki 偶联和缩合反应分两步合成了一系列新型 2-(pyridin-2-yl) H-咪唑并[1,2 - a ]吡啶衍生物，具有广泛的底物范围和良好的收率。使用不同的光谱技术表征合成化合物的结构。此外，研究了它们对α-葡萄糖苷酶的抑制活性。在各种合成的 2-(pyridin-2-yl) H - imidazo[1,2 - a ]pyridines 中，化合物5 g表现出最好的抑制效力，IC 50值为 3.7 μM，是标准抑制剂阿卡波糖的 18 倍（集成电路50  = 67.4 微米）。这些化合物的抗氧化活性通过使用体外2-azinobis-3-ethylbenzothiazoline-6-sulfonic acid (ABTS) 和 2,2-diphenyl-1-picrylhydrazyl (DPPH) 自由基生物测定来评估。进行分子对接以建立与靶酶的相互作用，这也证实了体

  DOI：

  10.1016/j.molstruc.2022.134238

文献信息

• [EN] WNT PATHWAY MODULATORS<br/>[FR] MODULATEURS DE LA VOIE WNT
  申请人：AGENCY SCIENCE TECH & RES

  公开号：WO2015094119A1

  公开（公告）日：2015-06-25

  The present invention relates to dihydropyrazolo[l,5-a]pyrimidine compounds of formula I, defined herein, as WNT pathways modulators, processes for making them, and pharmaceutical compositions comprising them. Methods of treatment of conditions mediated by WNT pathway signalling including cancer, fibrosis, stem cell and diabetic retinopathy, rheumatoid arthritis, psoriasis and myocardial infarction, comprising the compounds of formula I are also provided.

  本发明涉及式I的二氢吡唑并[1,5-a]嘧啶化合物，其在此处定义为WNT通路调节剂，以及制备它们的方法和包含它们的药物组合物。还提供了使用式I化合物治疗通过WNT通路信号传导介导的疾病的方法，包括癌症、纤维化、干细胞和糖尿病性视网膜病变、类风湿性关节炎、牛皮癣和心肌梗死。
• BIOLOGICALLY ACTIVE AMIDES
  申请人：Peterson John Matthew

  公开号：US20110230497A1

  公开（公告）日：2011-09-22

  The present invention is directed to biologically active amides which are ligands at the NPY Y5 receptor. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from certain disorders which comprises administering to the subject an amount of a compound of the subject invention. Furthermore, this invention also provides uses of a compound of the invention for the manufacture of a medicament for treating a subject suffering from certain disorders.

  本发明涉及生物活性酰胺，其是NPY Y5受体的配体。该发明还提供了一种制药组合物，包括本发明化合物的治疗有效量和药学可接受载体。本发明还提供了治疗患有某些疾病的受试者的方法，包括向受试者投予本发明化合物的量。此外，本发明还提供了一种利用本发明化合物制造治疗患有某些疾病的受试者的药物的用途。
• Wnt pathway modulators
  申请人：Agency for Science, Technology and Research

  公开号：US10189842B2

  公开（公告）日：2019-01-29

  The present invention relates to dihydropyrazolo[1,5-a]pyrimidine compounds of formula I, defined herein, as WNT pathways modulators, processes for making them, and pharmaceutical compositions comprising them. Methods of treatment of conditions mediated by WNT pathway signalling including cancer, fibrosis, stem cell and diabetic retinopathy, rheumatoid arthritis, psoriasis and myocardial infarction, comprising the compounds of formula I are also provided.

  本发明涉及作为 WNT 通路调节剂的式 I 所定义的二氢吡唑并[1,5-a]嘧啶化合物、其制造工艺以及包含它们的药物组合物。还提供了由 WNT 通路信号介导的病症的治疗方法，包括癌症、纤维化、干细胞和糖尿病视网膜病变、类风湿性关节炎、银屑病和心肌梗塞，其中包含式 I 化合物。
• WNT pathway modulators
  申请人：Agency for Science, Technology and Research

  公开号：US10870653B2

  公开（公告）日：2020-12-22

  The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein each of R1, R2, R3, R4, R5, W, X, Y, Z, and n is as defined herein.

  本发明涉及式（I）化合物、 或其药学上可接受的盐、溶液或多晶型，包括其所有同系物和立体异构体，其中 R1、R2、R3、R4、R5、W、X、Y、Z 和 n 中的每一个如本文所定义。
• WNT PATHWAY MODULATORS
  申请人：Agency for Science, Technology and Research

  公开号：EP3083631A1

  公开（公告）日：2016-10-26